Optimizing Transition of Care in Multiple Myeloma: Bridging the Gap Between Academic and Community Settings : Episode 2
Treating Patients Referred to Academic Centers for CAR T
Focusing on the transition of patients from community practices to academic centers, the panel discusses the initial evaluation and treatment processes, focusing on bridging therapy for patients awaiting CAR T.
EP: 1.Identifying Potential Candidates for CAR T-Cell Therapy
Now Viewing
EP: 2.Treating Patients Referred to Academic Centers for CAR T
EP: 3.CAR T-Cell Therapy: Leukapheresis Practices
EP: 4.Triaging and Prioritizing Patients with Multiple Myeloma
EP: 5.Transitioning Patients Back to Community Practices Following CAR T
EP: 6.Monitoring Adverse Events Following CAR T-Cell Therapy
EP: 7.Educating Patients on Complications Associated with CAR T-Cell Therapy
EP: 8.Improving Access for Patients Receiving CAR T-Cell Therapy
EP: 9.Collaborative Education for CAR T-Cell Therapy
EP: 10.Evaluating the Use of CAR T-Cell Therapy for Multiple Myeloma in Academic and Community Settings
- From the academic center's perspective, how do you approach the initial consultation and evaluation process for patients referred for CAR T-cell therapy from community practices?
- Are the processes similar across academic settings?
- How do you coordinate care and maintain communication with the academic center during the CAR-T treatment period?
- What is your approach to bridging therapy for patients awaiting CAR-T? How do you decide on the appropriate bridging regimen?
- How closely do you coordinate with academic centers around bridging therapy considerations and processes?
Recent Videos
Related Content
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025Podcast
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
